Overview

Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia

Status:
Completed
Trial end date:
2011-08-10
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the cognitive enhancing effects and tolerability of GSK239512 compared to placebo in patients with schizophrenia
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline